11th week of 2015 patent applcation highlights part 41 |
Patent application number | Title | Published |
20150071944 | STABLE ANTIBODY COMPOSITIONS AND METHODS OF STABILIZING SAME - The invention provides compositions and methods for inhibiting fractionation of immunoglobulins comprising a lambda light chain based on the observation that iron, in the presence of histidine, results in increased fragmentation of a recombinant fully human IgG molecule containing a lambda light chain due to cleavage in the hinge region. The invention further provides an aqueous pharmaceutical formulation comprising an antibody, or antigen-binding portion thereof, that binds the p40 subunit of IL-12/IL-23 and a buffer system comprising histidine, wherein the formulation has enhanced stability, including enhanced resistance to fragmentation. | 2015-03-12 |
20150071945 | METHODS OF ADMINISTERING ANTI-TNFALPHA ANTIBODIES - Methods of treating disorders in which TNFα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNFα (e.g., K | 2015-03-12 |
20150071946 | TUMOR-SPECIFIC RETROTRANSPOSON INSERTIONS - Described are biomarkers for neoplastic disease progression. Specifically, provided are methods of determining neoplastic disease progression by determining the presence of retrotransposon insertion. | 2015-03-12 |
20150071947 | METHODS OF IDENTIFYING GENE ISOFORMS FOR ANTI-CANCER TREATMENTS - Novel methods of classifying subjects as candidates for treatment with agent that inhibits or kills cancer associated mesenchymal cells, tumor initiating cancer cells, or cancer stem cells treatment and subsequent administration of the agent that inhibits or kills cancer associated mesenchymal cells, tumor initiating cancer cells, or cancer stem cells are disclosed within. | 2015-03-12 |
20150071948 | NOVEL IMMUNOGLOBULIN VARIANTS - The present invention relates to Fc variants with optimized Fc ligand binding properties, methods for their generation, Fc polypeptides comprising Fc variants with optimized Fc ligand binding properties, and methods for using same. | 2015-03-12 |
20150071949 | CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS (DM4) - New thiol and disulfide-containing maytansinoids bearing a mono or di-alkyl substitution on the α-carbon atom bearing the sulfur atom are disclosed. Also disclosed are methods for the synthesis of these new maytansinoids and methods for the linkage of these new maytansinoids to cell-binding agents. The maytansinoid-cell-binding agent conjugates are useful as therapeutic agents, which are delivered specifically to target cells and are cytotoxic. These conjugates display vastly improved therapeutic efficacy in animal tumor models compared to the previously described agents. | 2015-03-12 |
20150071950 | C-MET TARGETING COMPOUND-BIOACTIVE MATERIAL CONJUGATE AND USE THEREOF - Disclosed is a conjugate in which a c-Met targeting compound and a bioactive material are chemically conjugated with each other, and methods of use thereof. | 2015-03-12 |
20150071951 | VACCINE - The present invention relates to a vaccine comprising at least two fragments of Proprotein convertase subtilisin/kexin type 9 (PCSK9), wherein said at least two fragments comprise at least 8 consecutive amino acid residues of amino acid residues 150 to 170 and/or 205 to 225 of PCSK9 (SEQ ID No. 9). | 2015-03-12 |
20150071952 | SYNTHETIC PEPTIDES CAPABLE OF BINDING TO INFLUENZA HEMAGGLUTININ PROTEIN - The invention provides peptides capable of binding with influenza hemagglutinin (HA) protein blocking pH-induced shape change or aggregation of the influenza hemagglutinin (HA) protein. The invention also provides a druggable site in influenza Hemagglutinin protein, said druggable site comprises peptide sequences comprising conserved residues. | 2015-03-12 |
20150071953 | VARIANTS OF GROUP 6 ALLERGENS OF THE TRUE GRASSES HAVING REDUCED ALLERGENEITY DUE TO MUTAGENESIS OF PROLINE RESIDUES - The present invention relates to the preparation and use of recombinant variants of group 6 allergens of the Poaceae (true grasses), which are characterised by reduced IgE reactivity compared with known wild-type allergens and at the same time substantially retained reactivity with T-lymphocytes. | 2015-03-12 |
20150071954 | STABLE PEPTIDE MIMETICS OF THE HIV-1 GP41 PRE-HAIRPIN INTERMEDIATE - The present invention relates to a gp41 trivalent peptide mimetic having three gp41 N-peptides on a chemical scaffold which conformationally constrains the N-peptides into a trimeric coiled-coil to mimic gp41 presentation. The present invention also relates to N-peptides having the entire HIV gp41 NH2-terminal heptad repeat region and which are capable of forming gp41 peptide mimetics. Such peptide mimetics of HIV-1 gp41 pre-hairpin intermediates can be utilized in a vaccine for the treatment or prevention of HIV-1 infection through eliciting neutralizing antibodies. | 2015-03-12 |
20150071955 | GB VIRUS C (HEPATITIS G VIRUS) E2 GLYCOPROTEIN AS AN IMMUNOMODULATORY AGENT - GB virus C (GBV-C or hepatitis G virus) is a flavivirus that frequently leads to chronic viremia in humans. The invention provides compositions and methods involving GBV-C E2 polypeptides and peptides for use in modulating immune responses, including inhibition inflammation related to pathogenic T-cell activation. | 2015-03-12 |
20150071956 | NOVEL SURFACE EXPOSED HAEMOPHILUS INFLUENZAE PROTEIN (PROTEIN E; pE) - The present invention relates to a surface exposed protein (protein E, pE), a virnlence factor, which can be detected in | 2015-03-12 |
20150071957 | POLYPEPTIDE AND IMMUNE MODULATION - The present invention relates to | 2015-03-12 |
20150071958 | IMMUNOLOGICAL COMPOSITION FOR CLOSTRIDIUM DIFFICILE - The invention relates to methods and compositions for treating or inhibiting infection of | 2015-03-12 |
20150071959 | NEISSERIA MENINGITIDIS COMPOSITIONS AND METHODS THEREOF - In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in SEQ ID NO: 1 and a second polypeptide having the sequence set forth in SEQ ID NO: 2. In one embodiment, the composition includes about 120 μg/ml of a first polypeptide including the amino acid sequence set forth in SEQ ID NO: 1, 120 μg/ml of a second polypeptide including the amino acid sequence set forth in SEQ ID NO: 2, about 2.8 molar ratio polysorbate-80 to the first polypeptide, about 2.8 molar ratio polysorbate-80 to the second polypeptide, about 0.5 mg/ml aluminum, about 10 mM histidine, and about 150 mM sodium chloride. In one embodiment, a dose of the composition is about 0.5 ml in total volume. In one embodiment, two-doses of the composition induce a bactericidal titer against diverse heterologous subfamily A and subfamily B strains in a human. | 2015-03-12 |
20150071960 | HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS WITH ALTERED GLYCOSYL GROUPS - Glycosphingolipids (GSLs) bearing α-glucose (α-Glc) that preferentially stimulate human invariant NKT (iNKT) cells are provided. GSLs with α-glucose (α-Glc) that exhibit stronger induction in humans (but weaker in mice) of cytokines and chemokines and expansion and/or activation of immune cells than those with α-galactose (α-Gal) are disclosed. GSLs bearing α-glucose (α-Glc) and derivatives of α-Glc with F at the 4 and/or 6 positions are provided. Methods for iNKT-independent induction of chemokines by the GSL with α-Glc and derivatives thereof are disclosed. Methods for immune stimulation in humans using GSLs with α-Glc and derivatives thereof are provided. | 2015-03-12 |
20150071961 | SIDEROPHORE CONJUGATE IMMUNOGENIC COMPOSITIONS AND VACCINES - An immunogenic composition comprising a siderophore covalently linked to a pharmaceutically acceptable carrier molecule wherein the antigenicity of the siderophore moiety is sufficient to stimulate an immunologic response to the siderophore when the composition is circulating in the bloodstream of a human or non-human animal and vaccine. | 2015-03-12 |
20150071962 | SIMIAN ADENOVIRUS 41 AND USES THEREOF - Novel simian adenovirus 41 and two isolates thereof are described. Various uses of these isolates, including construction of a recombinant vector which comprises simian adenovirus 41 sequences and a heterologous gene under the control of regulatory sequences are provided. A cell line which expresses simian adenovirus 41 gene(s) is also disclosed. Methods of using the vectors and cell lines are provided. | 2015-03-12 |
20150071963 | CHIMERIC POLY PEPTIDES AND THE THERAPEUTIC USE THEREOF AGAINST A FLAVIVIRIDAE INFECTION - The invention relates to building a chimeric polypeptide used for preventing or treating a Flaviviridae infection. The use of the inventive chimeric polypeptide for producing recombinant viral vectors such as a measles living viral vector is also disclosed. | 2015-03-12 |
20150071964 | METHODS AND COMPOSITIONS FOR VIRAL VECTORED VACCINES - Methods and compositions are provided herein for non-invasive administration of an adenoviral vector (Ad-vector) vaccine with an adjuvant, such as a TLR3 agonist. These methods provide, for example, an increase in the immune response to the vaccine, an increase in the immunogenicity of the Ad-vector vaccine, an antigen sparing effect and improved safety with an effective protective immune response to the vaccine. | 2015-03-12 |
20150071965 | VIRAL VECTORS AND THEIR USE IN THERAPEUTIC METHODS - The invention provides viral vectors (e.g., herpes viral vectors) and methods of using these vectors to treat disease. | 2015-03-12 |
20150071966 | RODENT PLASMODIUM PARASITES AS PLATFORMS FOR A WHOLE-ORGANISM MALARIA VACCINE - A method for inducing protective immunity in a vertebrate host against malaria, by administering to the host a live rodent | 2015-03-12 |
20150071967 | Tolerisation-Inducing Composition - The present invention relates to a composition comprising a tolerogenic peptide and a GSK-3 inhibitor and uses thereof. The invention also relates to the use of a GSK-3 inhibitor to accelerate the peptide-mediated shift in secretion profile of lymphocytes from pro-inflammatory to anti-inflammatory cytokines. The GSK-3 inhibitor may be used to enhance antigen-specific immunotherapy. | 2015-03-12 |
20150071968 | IMMUNOSTIMULATORY COMPOSITIONS AND METHODS OF MANUFACTURE - Immune-stimulatory compositions and methods of manufacture are described with an unexpectedly greater immunostimulatory effect on the immune system than the individual components alone. The compositions include a combination of arabinogalactan protein (AGP) compounds, particularly those derived from honey or with similar activity to honey derived AGP's along with apisimin proteins, peptides or functional fragments thereof, particularly those isolated from royal jelly or apisimin produced via recombinant methods. | 2015-03-12 |
20150071969 | LEVALBUTEROL SALT - Levalbuterol L-tartrate affords crystals possessing properties desirable for use in a metered dose inhaler. | 2015-03-12 |
20150071970 | ADJUVANT OR PHARMACEUTICAL PREPARATION FOR TRANSDERMAL OR TRANSMUCOSAL ADMINISTRATION - An adjuvant for transdermal or transmucosal administration which comprises at least one substance selected from an aliphatic alcohol, a free fatty acid and a fatty acid derivative but does not contain a substance represented by the following formula: wherein R | 2015-03-12 |
20150071971 | SUBLINGUAL BUPRENORPHINE SPRAY - The invention provides sublingual formulations containing buprenorphine, a pharmaceutically acceptable salt thereof, or a derivative thereof. The invention further provides sublingual formulations containing buprenorphine and naloxone, pharmaceutically acceptable salts thereof or derivatives thereof. The invention further provides a method of treating pain or opioid dependence by administering sublingual formulations containing buprenorphine, a pharmaceutically acceptable salt thereof, or a derivative thereof to a patient in need thereof. | 2015-03-12 |
20150071972 | NICOTINE-CONTAINING PHARMACEUTICAL COMPOSITION - A composition intended to be employed for therapeutic purposes incorporates a nicotinic compound, a sugar substitute, and a sugar alcohol syrup. Representative forms of nicotine include free base (e.g., as a mixture of nicotine and microcrystalline cellulose), a nicotine salt (e.g., as nicotine bitartrate) or nicotine polacrilex. The composition is useful for treatment of central nervous system conditions, diseases, and disorders, and as a nicotine replacement therapy. | 2015-03-12 |
20150071973 | COLORED METALLIC PIGMENT AND METHOD FOR PRODUCING THE SAME - A colored metallic pigment of the present invention includes a metallic pigment, a first coating layer formed on the surface of the metallic pigment, and a coloring pigment adhered to the surface of the first coating layer. The first coating layer is formed from radical-polymerizable resin or a first compound, and the first compound is an oxide or a hydroxide of at least one element selected from the group consisting of Al, Si, Ti, Cr, Zr, Mo and Ce. | 2015-03-12 |
20150071974 | COMPOUNDS WHICH INHIBIT NEURONAL EXOCYTOSIS - Compounds of general formula (I): R | 2015-03-12 |
20150071975 | FOAMABLE SUNSCREEN FORMULATION - The present application relates to sunscreen formulations, including foamable sunscreen formulations, that comprise zinc oxide and titanium dioxide particles, suitably in the size range of about 1-100 nm. The compositions suitably produce a minimal residual whitening effect when applied to a skin surface. | 2015-03-12 |
20150071976 | Shampoo Compositions With Increased Deposition Of Polyacrylate Microcapsules - A shampoo composition that increases the deposition and retention of benefit agent containing polyacrylate microcapsules onto hair during the cleansing process. The shampoo composition is based on the combination of anionic charged polyacrylate microcapsules, cationic deposition polymers, detersive surfactant, and a carrier. | 2015-03-12 |
20150071977 | Delivery Particle - The present application relates to encapsulated benefit agents, compositions comprising such encapsulated benefit agents and processes for making and using compositions comprising such encapsulated benefit agents. Such encapsulated benefit agents eliminate or minimize one or more of the drawbacks of current encapsulated benefit agents and thus provide formulators with additional perfume delivery opportunities. | 2015-03-12 |
20150071978 | CLOTHING AND COVERING SYSTEM WITH VARIOUS FUNCTIONS - Clothing and covering system with various functions comprising at least one item, having at least one layer, at least one fabric, and at least one function. At least one function is selected from the group consisting of wearing on body, fashion display, preventing snow, preventing wind, preventing sun, preventing dust and dirt, support, comfort, performance, protection, insulation, warmth, coverage, storage, containment, drying, wiping, drainage, security, housing, water flotation, thermal insulation, heat resistance, bullet proofing, sun screening, non ironing, breasts shaping, arch support, seamless footwear, bandaging, cover polarizing, pressure addition, cover planting, electricity generation, food storage with coated paper, odor absorption, aromatherapy, moisturizing, cleansing, dust trapping, glow-in-the-dark, water and leakage proofing, and ingredient addition. Leakproof clothing and covering can control and prevent both leakage of body discharge and secretion, and leakage of rain and water. Clothing and covering with ingredient addition includes flavoring ingredient, cleansing ingredient, nutritional ingredient, and health ingredient. | 2015-03-12 |
20150071979 | Sodium Bicarbonate Product - A sodium bicarbonate product comprises particles containing sodium bicarbonate and an organic material that is a solid at ambient temperature. The particles have a structure comprised of individual crystallites of sodium bicarbonate attached together in the particle. More than 95% by volume of the particles have a size less than 200 μm. Particles of the product are hollow and are formed of an outer shell of the crystallites. The product may be used, for example, as a leavening agent in the production of cooked foods. The product may be produced by spray drying a solution or slurry dissolved organic material and dissolved sodium bicarbonate. The sodium bicarbonate may be present as a suspension. | 2015-03-12 |
20150071980 | FORMATION OF NANOSIZED METAL PARTICLES ON A TITANATE CARRIER - Methods directed to the synthesis of metal nanoparticles are described. A formation process can be carried out at ambient temperature and pressure and includes the deposition of metal ions on a titanate carrier according to a chemical deposition process followed by exposure of the metal ions to a reducing agent. Upon the exposure, nanoparticles of the reduced metal are formed that are adhered to the titanate carrier. | 2015-03-12 |
20150071981 | SUSTAINED-RELEASE DRUG CARRIER COMPOSITION - The present invention provides compositions for extended release of an active ingredient, comprising a lipid-saturated matrix formed from a biodegradable polymer. The present invention also provides methods of producing the matrix compositions and methods for using the matrix compositions to provide controlled release of an active ingredient in the body of a subject in need thereof. | 2015-03-12 |
20150071982 | ANTIMICROBIAL POLYMER LAYERS - The invention provides compositions comprising a plurality of polymer layers for preventing or inhibiting microbial infections. Specifically, the invention provides a combination of a cationic polymer layer that resists adhesion of a microbe to its surface and an anionic polymer layer that releases a cationic anti-microbial agent in response to a change in pH or electrostatic balance. | 2015-03-12 |
20150071983 | BIOACTIVE POROUS BONE GRAFT COMPOSITIONS WITH COLLAGEN - Bioactive porous bone graft implants in various forms suitable for use in bone tissue regeneration and/or repair, as well as methods of use are provided. The implants are formed of bioactive glass and have an engineered porosity. The implants may be contained in polymer for enhanced clinical results and better handling. | 2015-03-12 |
20150071984 | Controlled and Localized Release of Retinoids to Improve Neointimal Hyperplasia - Controlled release vascular implants, such as vascular grafts, stents, wraps, and gels comprising a biocompatible polymer and all trans retinoic acid (ATRA), or its derivatives, can be used to treat, prevent, or inhibit thrombosis and/or neointimal hyperplasia which may otherwise be induced by prosthetic implantation. In particular, the implants herein can inhibit smooth muscle cell proliferation, neointimal hyperplasia, and upregulate antithrombotic genes and nitric oxide production in the vasculature. Further, the implants are capable of delivering controlled and predictable localized concentrations of ATRA. | 2015-03-12 |
20150071985 | HAEMOSTATIC WOUND DRESSING - Haemostatic wound dressings are described. The dressings comprise a non-colloidal porous dressing material, and a plurality of fibrinogen-binding peptides immobilised to the non-colloidal porous dressing material, wherein each fibrinogen-binding peptide comprises: an amino acid sequence Gly-Pro-Arg-Xaa (SEQ ID NO: 1) at an amino-terminal end of the peptide, wherein Xaa is any amino acid other than Val, preferably Pro, Sar, or Leu; or an amino acid sequence Gly-His-Arg-Xaa (SEQ ID NO: 2) at an amino-terminal end of the peptide, wherein Xaa is any amino acid other than Pro. The dressings are able to accelerate haemostasis without requiring enzymatic activity. In particular, the dressings to do not rely on the action of exogenous thrombin, and can be stored long-term at room temperature in solution. Methods of making the dressings, and use of the dressings to control bleeding are also described. | 2015-03-12 |
20150071986 | METHOD FOR BLOCKING TUMOUR GROWTH - The present invention concerns a pharmaceutical composition comprising virtosomes isolated from non-dividing cells or the medium in which the cells are grown, for use in the inhibition of tumour growth and/or prevention of metastases. | 2015-03-12 |
20150071987 | IMMUNOSTIMULATORY COMPOSITIONS, PARTICLES, AND USES RELATED THERETO - In some embodiments, described herein is a method of tumor treatment or tumor vaccination. The method generally comprises applying to a human being in need thereof a tumor therapeutic composition or tumor vaccine defined herein. The tumor therapeutic composition or tumor vaccine can be produced by protein transfer of glycosyl-phosphatidylinositol (GPI)-anchored immunostimulatory or costimulatory molecules. | 2015-03-12 |
20150071988 | Sterically Stabilized Carrier For Aerosol Therapeutics, Compositions And Methods For Treating The Respiratory Tract Of A Mammal - This invention comprises a sterically stabilized liposome carrier encapsulating a selected drug for the aerosol delivery of the drug effectual in the treatment of a mammal, a composition containing the sterically stabilized liposome carrier and a drug effective for the treatment a mammal as an aerosol and a method of treatment using the composition. The composition provides effective treatment for the longer of a period of time at least twice as long as the drug alone or up to at least one week. | 2015-03-12 |
20150071989 | LIPOSOMES FOR HEMATOLOGICAL TUMORS - Targeted liposomes containing chemotherapeutic compounds of Formula (I) are provided for treating hematological cancers. The targeted liposomes can be targeted to cancer cells (e.g., malignant B cells) by attachment to an antibody or antibody fragment of a suitable cell surface antigen, e.g., CD22. The targeted liposomes have higher IC | 2015-03-12 |
20150071990 | Method of Treating Patients with a Mucinous Glycoprotein (MUC-1) Vaccine - The present invention provides a method for treating an individual who is afflicted with a cancer, such as non-small cell lung cancer or prostate cancer, by administering to that individual a MUC-1-based formulation. The formulation may be a MUC-1 based liposomal vaccine formulation. | 2015-03-12 |
20150071991 | DRUG HAVING REGULATORY CELL LIGAND CONTAINED IN LIPOSOME - A liposome containing a regulatory cell ligand such as α-galactosyl ceramide or β-galactosyl ceramide is employed as the active ingredient of a drug for preventing or treating immune diseases etc. | 2015-03-12 |
20150071992 | CONCENTRATED, INHALABLE ANTIBIOTIC FORMULATION - A concentrated inhalable formulation of an antibiotic drug such as ciprofloxacin is disclosed. The antibiotic is formulated with sodium acetate and liposome which incorporate antibiotic. The formulation is aerosolized and inhaled for treatment of respiratory tract infections and other medical conditions. | 2015-03-12 |
20150071993 | Compositions and Methods for Improving Sleep Using A Nutraceutical Formulation - Provided are supplemental compositions for a nutraceutical formulation and methods for administering the same to a user for inducing or maintaining sleep as well as for alleviating pain to improve sleep using a formulation of ingredients comprising of extract of ashwagandha, extract of lavender, extract of valerian, extract of hops, melatonin, magnesium, vitamin B12, and zinc, and/or devil's claw, bromelain and boswellia. | 2015-03-12 |
20150071994 | GASTROINTESTINAL SITE-SPECIFIC ORAL VACCINATION FORUMULATIONS ACTIVE ON THE ILEUM AND APPENDIX - The invention provides oral vaccine formulations which deliver an antigen in the vicinity of the distal ileum and the area of the ileal Brake and/or the appendix. These vaccines are useful in the treatment and/or prevention of variety of disorders, including viral and bacterial infections and cancers. Related methods of treatment which use the oral vaccine formulations of the invention are also provided. | 2015-03-12 |
20150071995 | ABUSE RESISTANT FORMS OF EXTENDED RELEASE HYDROCODONE, METHOD OF USE AND METHOD OF MAKING - An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (GI) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided. | 2015-03-12 |
20150071996 | FORMULATION AND MANUFACTURING PROCESS FOR CALCIUM ACETATE CAPSULES - The present invention relates to a pharmaceutical calcium acetate formulation and a process for making the same. In particular, the present invention relates to a calcium acetate capsule formulation comprising granules comprising calcium acetate along with other formulation adjuvants contained within a pharmaceutically acceptable capsule. | 2015-03-12 |
20150071997 | Microgels for Encapsulation of Cells and Other Biologic Agents - Methods of encapsulating cargo in a microgel droplet, microgel droplets prepared according the provided methods, and methods of use thereof are disclosed. The methods of preparing cargo-encapsulated microgels generally include flowing through a flow-focusing nozzle of a microfluidic device a macromer phase, an oil phase, and a crosslinker phase to form microgel droplets by oil-water emulsion. The phases are pumped, injected, or flowed through the microfluidic device such that as the macromer phase approaches the flow focusing nozzle, the co-flowing oil phase shields the macromer from contact with the crosslinker phase until flow instability occurs and macromer phase droplets form. After flow instability occurs, the crosslinker diffuses from the crosslinker phase into the droplets in an effective amount to covalently crosslink the macromer into a microgel network encapsulating the cargo in the crosslinked macromer. Microgels prepared according to the disclosed methods and methods of use thereof are also provided. | 2015-03-12 |
20150071998 | ABUSE RESISTANT FORMS OF IMMEDIATE RELEASE OXYMORPHONE, METHOD OF USE AND METHOD OF MAKING - An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (GI) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided. | 2015-03-12 |
20150071999 | Novel RNAi Molecule Delivery Platform Based on Single-siRNA and shRNA Nanocapsules - Novel siRNA and shRNA nanocapsules and delivery methods are disclosed herein. These siRNA and shRNA nanocapsules and delivery methods are highly robust and effective. This invention provides a platform for RNAi delivery with low toxicity and long intracellular half-life for practical therapeutic applications. | 2015-03-12 |
20150072000 | METHOD FOR PRODUCING ENTERIC ALGINATE MICROCAPSULES VIA IONIC GELATION CONTAINING DICLOFENAC OR ONE OF THE SALTS THEREOF AND MULTIPARTICLED PHARMACEUTICAL COMPOSITION CONTAINING THEM - Method for producing enteric microcapsules without coating, containing diclofenac or one of the salts thereof with satisfactory anti-inflammatory activity and low gastric aggressiveness; and a pharmaceutical composition containing them. The method comprises a) preparing a mixture in water-ethanol with an alginate salt, adding diclofenac or one of the salts thereof previously diluted with a surfactant and sodium bicarbonate; b) adding the previous solution to a solution with a calcium salt; c) resuspending the microcapsules obtained and isolated in an aqueous solution of the alginate salt; and d) isolating, drying and sieving through 1000 and 250 micron meshes the microcapsules obtained; and selecting the fraction comprised between both meshes. The pharmaceutical composition can be an oral composition, tablets, chewable tablets, or a powder for suspension in water. | 2015-03-12 |
20150072001 | NOVEL PHARMACEUTICAL FORMULATION CONTAINING A BIGUANIDE AND A THIAZOLIDINEDIONE DERIVATIVE - A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a thiazolidinedione derivative is herein disclosed and described. | 2015-03-12 |
20150072002 | USE OF POLYOLS TO OBTAIN STABLE POLYMORPHOUS FORMS OF RIFAXMIN - Polyols stabilize polymorphous form of rifaximin, in particular the β form. When polyols having at least two hydroxy groups are added to rifaximin powder, polymorph β is stable and remains stable in time independently from the environment humidity. In this invention a method to prepare formulations constituted by pure and stable polymorphous forms able to give a pharmaceutical product is described. | 2015-03-12 |
20150072003 | FORMULATIONS - The present invention relates to a hygroscopic matrix based composition, a process for the preparation thereof and its use in the treatment of diseases. | 2015-03-12 |
20150072004 | GABA ANALOG PRODRUG SUSTAINED RELEASE ORAL DOSAGE FORMS - Sustained release oral dosage forms of a gabapentin prodrug, 1-{[(α-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid, are disclosed. The dosage forms are useful for treating or preventing diseases and disorders for which gabapentin is therapeutically effective. | 2015-03-12 |
20150072005 | ASPIRIN FORMULATION FOR INCREASED EFFICACY - Provided are methods for enhancing the efficacy of aspirin. Also provided are methods for reducing pain or preventing or treating heart attack, stroke or blood clot in a subject in need thereof. The methods entail orally administering to the subject a first composition comprising a first amount of aspirin, and a second composition comprising a second amount of aspirin, wherein the first composition is formulated so as to, upon administration, disintegrate or dissolve intraorally providing rapid release of the aspirin of the first composition in the subject, and wherein the second composition is formulated to be substantially more difficult than the first composition to disintegrate or dissolve intraorally but is ingestible and releasable in the gastrointestinal track of the subject. The method can further include administering to the subject a painkiller or an agent suitable for treating a cardiovascular disease or condition. | 2015-03-12 |
20150072006 | Pharmaceutical Formulations - The invention relates to drug preparations with controlled active ingredient released in the form of microtablets which contain, as active ingredient, flupirtin or one of its physiologically compatible salts, and to processes for their production. | 2015-03-12 |
20150072007 | THERAPEUTIC STEM CELL COMPOSITION AND STIMULANT, FACILITATOR, ACCELERATOR, AND SYNERGIZER THEREOF, GROWTH FACTOR, ANTI-INFLAMMATORY COMPOSITION AND USES THEREOF - The present invention relates to a non-invasive medical therapy and a composition for avoiding organ transplantation, or controlling biological rejection of transplanted organs, or treating organs under consideration for replacement by transplant, and otherwise treating aged, diseased and/or abnormal tissues and/or organs. More specifically, the non-invasive medical therapy involves administering to a patient an elemental nutritional feeding comprising a free amino acid profile simulating and/or replicating a targeted diseased or transplanted tissue and/or organ. The subject invention provides methods of inactivating reactive component epitopes of moieties pathogenic substances or producing immunogenic compositions containing pathogenic substances comprising contacting pathogenic substances, or compositions containing pathogenic substances, with super critical carbon dioxide or liquid nitrogen. Similar benefits are produced using high HLB surfactants also reducing carcinogenic factors. In various embodiments, the pathogenic reactive components, epitopes, moieties or substances are inactivated and processed into immunogenic compositions. The subject invention also provides oral mucosal delivery systems for the subject therapeutic compositions and/or medications, and/or vaccines that avert the need for parenteral administration in the medical and veterinary fields. | 2015-03-12 |
20150072008 | NONWOVEN MEMBRANE AS A DRUG DELIVERY SYSTEM - The invention defines a nonwoven membrane for the controlled and sustained release of a therapeutic or cosmetic active agent in the area of the body to be treated. This nonwoven membrane comprises one single type of biocompatible electrospun nanofibers and microparticles of at least one therapeutic or cosmetic active agent which are entangled between the nanofibers, the active agent having a low water solubility. | 2015-03-12 |
20150072009 | Mesoporous Silica Compositions for Modulating Immune Responses - A composition comprising mesoporous silica rods comprising an immune cell recruitment compound and an immune cell activation compound, and optionally comprising an antigen such as a tumor lysate. The composition is used to elicit an immune response to a vaccine antigen. | 2015-03-12 |
20150072010 | Combination of Azelastine and Mometasone for Nasal Administration - A pharmaceutical product or formulation, which comprises azelastine or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, and a steroid, or a pharmaceutical acceptable salt, solvate or physiologically functional derivative thereof, preferably the product or formulation being in a form suitable for nasal or ocular administration. | 2015-03-12 |
20150072011 | CARBOXYLVINYL POLYMER-CONTAINING NANOPARTICLE SUSPENSIONS - The present invention generally relates to suspension compositions having a carboxyvinyl polymer such as a carbomer, a galactomannan such as guar, and a borate compound. A sparingly soluble particulate compound such as nepafenac is also included in the compositions. The sparingly soluble particulate compound has a small particle size to enhance bioavailability of the compound. | 2015-03-12 |
20150072012 | NOVEL HIGHLY BIOAVAILABLE, WATER SOLUBLE AND SUSTAINED RELEASE NANOFORMULATIONS HYDROPHOBIC PLANT DERIVED COMPOUNDS AND EXTRACTS - A highly bioavailable, water soluble, sustained release nanoformulation comprising a hydrophobic plant derived compound(s) in an emulsifier phase, and aqueous phase. The formulation provides sustained release of the hydrophobic plant derived compound(s) over a 24 hr time period. A process for preparation of the water soluble nanoformulation is described. | 2015-03-12 |
20150072013 | INTRA-ARTICULARLY SUPPLEMENTATION METHOD FOR TREATING JOINT DISEASES AND INJURIES - A hydrogel bead for intra-articular supplement made by: | 2015-03-12 |
20150072014 | Pharmaceutical Compositions of Sodium Picosulfate, Magnesium Oxide and Citric Acid - The present invention relates to pharmaceutical compositions of sodium picosulfate, magnesium oxide and citric acid. In particular, the invention relates to pharmaceutical compositions comprise granules having a layer of sodium picosulfate on neutral carrier/s. The invention also relates to processes for the preparation of such compositions and use thereof for bowel cleansing. | 2015-03-12 |
20150072015 | METHOD FOR PRODUCING GRANULES - In a production process of granules containing a biologically active substance, variation in the elation profile of the biologically active substance is reduced by heating the temperature of granules to about 50° C. or higher and maintaining the temperature for about 1 minute or longer. By setting the spray speed to about 90 mg/min or more per 1 g of cores when a spray agent fox a primary agent containing the biologically active substance is sprayed while spraying a binding liquid to the cores and setting the total feeding weight per unit area for a centrifugal fluidized bed coating granulation machine to about 1.5 g/cm | 2015-03-12 |
20150072016 | Microparticles with adsorbed polynucleotide-containing species - Microparticles with adsorbed polynucleotide-containing species, compositions containing the same, methods of making such microparticles, and uses thereof are disclosed. The microparticles comprise (a) a biodegradable polymer, such as a polyhydroxy butyric acid, a polycaprolactone, a polyorthoester, a polyanhydride, or a polycyanoacrylate, (b) a cationic surfactant such as cetyltrimethylammonium bromide, (c) and a polynucleotide-containing species adsorbed on the surface of the microparticles, wherein the polynucleotide-containing species constitutes at least 5 percent of the total weight of said microparticles. Examples of polynucleotide-containing species include polynucleotide-containing immunological adjuvants, such as CpG oligonucleotides, and polynucleotide-containing species that encode polypeptide-containing antigens, such as RNA and DNA vector constructs. Methods of delivering a therapeutic amount of a polynucleotide-containing species to a host animal, methods of stimulating an immune response, methods of treating a host animal having a pathogenic organism infection, methods of immunizing a host animal against infection by a pathogenic organism, and uses of the microparticle compositions for vaccines are also provided. | 2015-03-12 |
20150072017 | CARRIER MATERIALS FOR PROTEIN DELIVERY - Osteogenic implants, carriers and concentrates are described, along with methods of making and using the same. The implants include a carrier and, optionally, an osteoinductive agent. The carrier includes a mineral component, a binder and, optionally, a collagen additive, while the osteoinductive agent may be a protein such as a bone morphogenetic protein. | 2015-03-12 |
20150072018 | BIOLOGIC PROSTHESIS AND METHODS OF PRODUCTION AND USE - Products, processes, compositions, kits, and methods are provided for cartilage-derived implants. The implants can exhibit resistance to enzyme (e.g., collagenase, protease, etc.) digestion compared to the source tissue from which they were derived while still having one or more mechanical properties comparable to the source tissue from which they were derived. The implants can also have a plurality of molecular bridges between molecules of the cartilaginous material. The molecular bridges can connect one or more collagen fibrils and/or/with one or more glycosaminoglycans. The implants can also be treated with cationic detergent, packaged and sterilized with or without additional components, and surgically implanted into subjects. | 2015-03-12 |
20150072019 | FGFR INHIBITOR FOR USE IN THE TREATMENT OF HYPOPHOSPHATEMIC DISORDERS - The present invention relates generally to 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimid-4-yl}-1-methyl-urea or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimid-4-yl)-1-methyl-urea or a pharmaceutically acceptable salt or solvate thereof for use in the treatment of X-linked hypophosphatemic rickets (XLH), autosomal dominant hypophosphatemia rickets (ADHR), autosomal recessive hypophosphatemic rickets (ARHR), tumor-induced osteomalacia, post-renal transplant hypophosphatemia, epidermal nevus syndrome, osteoglophonic dysplasia or McCune-Albright syndrome. | 2015-03-12 |
20150072020 | Dexanabinol or a Derivative Thereof for Use in the Treatment of Cancer in Dose Ranges of 2-30 mg/kg - There is described a method of treating cancer in a patient wherein the method comprises the administration of dexanabinol, or a derivative thereof, in an amount of from about 2 mg/kg to about 30 mg/kg, based on the weight of the patient. | 2015-03-12 |
20150072021 | Methods and Kits for Predicting Outcome and Methods and Kits for Treating Breast Cancer with Radiation Therapy - The application describes methods and kits for screening subjects with breast cancer to determine if the breast cancer will be responsive to a post-mastectomy breast cancer therapy including radiation. The application further describes methods and kits for treating subjects with post-mastectomy breast cancer by screening them for the likelihood of the effectiveness of treating the cancer with a therapy including radiation and administering the therapy in subjects when it is found that radiation is likely to be effective. | 2015-03-12 |
20150072022 | FRACTIONAL C-REACTIVE PROTEIN (fracCRP) ANTIBODIES AND ASSAYS - Antibodies and antigen-binding fragments of antibodies that bind to human fractional C-Reactive Protein (fracCRP), kits containing these antibodies and antibody fragments, and assays using these antibodies and antibody fragments. | 2015-03-12 |
20150072023 | INHALATION OF NITRIC OXIDE FOR TREATING RESPIRATORY DISEASES - A method of treating a human subject which is effected by intermittent inhalation of gaseous nitric oxide at a concentration of at least 160 ppm is disclosed. The method can be utilized for treating a human subject suffering from, or prone to suffer from, a disease or disorder that is manifested in the respiratory tract, or from a disease or disorder that can be treated via the respiratory tract. The disclosed method can be effected while monitoring one or more of on-site and off-site parameters such as vital signs, methemoglobin levels, pulmonary function parameters, blood chemistry and hematological parameters, blood coagulation parameters, inflammatory marker levels, liver and kidney function parameters and vascular endothelial activation parameters, such that no substantial deviation from a baseline in seen in one or more of the monitored parameters. | 2015-03-12 |
20150072024 | SODIUM NITRITE-CONTAINING PHARMACEUTICAL COMPOSITIONS - Provided herein are pharmaceutically acceptable sodium nitrite and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-volatile organic carbon in a sodium nitrite-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium nitrite. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium nitrite. | 2015-03-12 |
20150072025 | SODIUM NITRITE-CONTAINING PHARMACEUTICAL COMPOSITIONS - Provided herein are pharmaceutically acceptable sodium nitrite and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-volatile organic carbon in a sodium nitrite-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium nitrite. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium nitrite. | 2015-03-12 |
20150072026 | Anti-inflammatory ion and uses thereof - The present invention related to a pharmaceutically acceptable amount of ammonium salt as an anti-inflammation agent thereof, and a pharmaceutical composition, a functional cosmetic composition, a health food, health beverages, a food additive and animal feeds containing the same. | 2015-03-12 |
20150072027 | METHOD AND APPARATUS FOR TREATING PEST - A device for treating pests and method for using the same. The device comprises an effective amount of endod. The device can be placed in a body of water wherein the endod treats the pests. Additionally the device can be placed in a pipe whereby a combination of the endod and the mechanical force of the water removes the pests in the pipe. | 2015-03-12 |
20150072028 | EXTRACTS AND ISOLATED COMPOUNDS FROM CAKILE ARABICA FOR TREATMENT OF ULCER - The present invention relates to extracts, compounds isolated from | 2015-03-12 |
20150072029 | MATERIALS AND METHODS FOR REDUCTION OF PROTEIN TAU AND TREATMENT OF NEURODEGENERATIVE DISEASES - The subject invention provides a myricanol compound that is in predominant form of (+)-αR,11S-myricanol as compared to (−)-αS,11R-myricanol. In one embodiment, the (+)-αR,11S-myricanol is isolated from | 2015-03-12 |
20150072030 | BIOCOMPATIBLE TEA TREE OIL COMPOSITIONS - There are disclosed non-phytotoxic biocompatible compositions comprising tea tree oil (TTO), as well as their use and methods for their production. Other embodiments are also disclosed. | 2015-03-12 |
20150072031 | SKIN TEMPERATURE ELEVATING AGENT, AND COSMETIC COMPOSITION, FOOD AND SUNDRY ARTICLE CONTAINING THE SAME - Disclosed here is a method for elevating skin temperature comprising administering to a subject in need thereof a composition comprising an effective amount of one or more compounds selected from the group consisting of dihydro-β-ionol and 4-methoxystyrene. Also disclosed is a method for elevating skin temperature comprising administering to a subject in need thereof a composition comprising an effective amount of one or more compounds selected from the group consisting of dihydro-β-ionol, 4-methoxystyrene, clary sage extract, Japanese peppermint extract, juniper berry extract, and geraniol. | 2015-03-12 |
20150072032 | EXTRACT OF ADLAY BRAN AND USES THEREOF - The present invention provides a composition comprising extract of adlay bran, wherein the adlay bran extract comprises C1 to C7 alcohol extract of adlay bran (A) and carbon dioxide supercritical fluid extract of adlay bran (B). Preferably, the extract of adlay bran has effects in treating a skin and/or subcutaneous tissue disease and in lowering interleukin (IL)-1α, interleukin-1⊖, interleukin-6, tumor necrosis factor (TNF)-α, interleukin-8, prostaglandin-2 (PGE2) and/or C-Reactive Protein (CRP). | 2015-03-12 |
20150072033 | EXTRUDED NON-REPLICATING PROBIOTIC MICRO-ORGANISMS AND THEIR HEALTH BENEFITS - The present invention generally relates to the field of pro biotic micro-organisms, in particular to the field of non-replicating probiotic micro-organisms. Embodiments of the present invention relate to compositions comprising probiotic microorganisms that were rendered non-replicating by extrusion. Such compositions may be used to treat or prevent disorders that are related to a compromised immune system. | 2015-03-12 |
20150072034 | TREAD STRIP CURING STATION - A curing station for curing a tread strip, having a flat curing mold; a gripper which grips a portion of the cured tread strip inside the curing mold; an actuating device which, at the end of the curing process, moves the gripper to gradually extract the cured tread strip from the curing mold; and a guide device which, as the cured tread strip is extracted, is positioned over the curing mold, and has a main roller, about which the extracted part of the cured tread strip winds, and a secondary roller smaller in diameter than, and positioned parallel to and alongside, the main roller. | 2015-03-12 |
20150072035 | Installations For Manufacturing Biaxially Oriented Tubing And The Tubing Itself - The production of a biaxially oriented tube from thermoplastic material, wherein a tube in preform condition is extruded from thermoplastic material using an extruder having an extruder die head with an inner die member that forms a lumen in the tube in preform condition. The tube in preform condition is subjected to a temperature conditioning. Use is made of a expansion device comprising a non-deformable expansion part having a gradually increasing diameter to a maximum diameter, which expansion part is contacted by the tube and exerts an expanding force so as to bring about expansion of the tempered tube in circumferential direction. The method comprises drawing the tempered tube over the expansion device using a drawing device, in such a manner that said tube is transformed from a tube in preform condition into a biaxially oriented tube with thermoplastic material which is oriented in axial direction and in circumferential direction of the tube. | 2015-03-12 |
20150072036 | APPARATUS FOR THE SHAPING OF PLASTICS MATERIAL PRE-FORMS WITH A CLEAN ROOM - An apparatus comprises a conveying device and a plurality of blow moulding stations arranged on the conveying device. Each blow moulding station includes a blow mould. A clean room is provided inside which the plastics material pre-forms are conveyed. The blow mould has two lateral parts and a bottom part that jointly form a cavity inside which a plastics material pre-form is shaped into a plastics material container. A drive device moves the lateral parts or the bottom part of the blow mould. A coupling device couples the drive device to a lateral part. A mounting device mounts the coupling device. | 2015-03-12 |
20150072037 | CUTTER BLADE DRIVINGA ND POSITIONING CONTROL STRUCTURE FOR PLASTIC PELLETIZING MACHINE - A cutter blade driving and positioning control structure formed of a rotary drive, a transmission unit, a sliding unit, a linear motor and a cutter unit and used in a plastic pelletizing machine for making plastic pellets is disclosed. The rotary drive provides a rotary driving force for driving the transmission unit to rotate the cutter unit. The linear motor is adapted to reciprocate the transmission unit, moving the cutter unit back and forth rapidly with minimized energy consumption. | 2015-03-12 |
20150072038 | MACHINE FOR MANUFACTURING CONCRETE UWALL TYPE CONSTRUCTION BLOCKS BY MOLDING EACH CONCRETE U-WALL CONSTRUCTION BLOCK FROM CONCRETE POURED ABOUT A BLOCK CAGE MADE FROM REINFORCING MATERIAL WHILE SAID BLOCK CAGE IS LOADED WITHIN SAID MACHINE - A machine for and method of manufacturing concrete U-wall type construction blocks by molding each concrete u-wall construction block from concrete poured about a block cage made from reinforcing material while said block cage is loaded within the machine. The method involves providing a system of molding jacket panels, including a core molding assembly having a pair of inside stem jacket panels that are adjustably supportable in a substantially parallel manner during a molding process, and arranged is such a manner that the front wall portion is molded in downwardly facing direction toward a horizontal support surface and completely enclosed in one or more molding jacket panels. Before block molding operations, the thickness of the front wall portion of the U-wall construction block is set by determining the thickness of a front wall surface liner and installing the front wall surface forming liner within the system of molding jacket panels. | 2015-03-12 |
20150072039 | PRODUCTION METHOD AND PRODUCTION DEVICE OF FILM HAVING FINE IRREGULAR PATTERN ON SURFACE - A method for producing a film having a fine irregular pattern intermittently includes feeding a film to be processed intermittently from upstream side to the vicinity of the surface of a die having a fine irregular pattern, transferring the pattern to the surface of the film by pressing the film against the surface of a die, stripping the processed film on which a pattern is formed from the surface of a die, and then feeding a new film to be processed to the die, wherein the processed film is stripped from the surface of a die by gripping and moving the processed film to the upstream side, and then the processed film is fed by a length of intermittent feed to the surface of a die while preventing the processed film from creasing. | 2015-03-12 |
20150072040 | COVER SHEET SUPPLY APPARATUS HAVING VARIABLE CLAMP FOR THERMOFORMING MACHINE - Disclosed herein is a cover sheet supply apparatus having variable clamps for a thermoforming machine. The apparatus includes a support frame ( | 2015-03-12 |
20150072041 | APPARATUS FOR SCREENING OFF RADIATION DURING THE STERILIZATION OF CONTAINERS - An apparatus for the sterilization of containers with a conveying device which conveys the containers along a pre-determined conveying path (P), with a sterilization device which acts upon at least one area of the containers with charge carriers in the course of the sterilization, with a screening apparatus for screening off beams from the environment, which has at least two screening bodies which are arranged with respect to each other in such a way that one screening body is situated on the side of the screening apparatus facing the conveying path (P) and one screening body is situated on the one facing away from it, wherein the screening bodies are thermally insulated from each other. | 2015-03-12 |
20150072042 | EFFECTS OF A DECAFFEINATED GREEN COFFEE EXTRACT ON BODY WEIGHT CONTROL BY REGULATION OF GLUCOSE METABOLISM - A method of controlling body weight in humans by administering an amount of decaffeinated green coffee extract effective to treat a subject. A preferred green coffee extract contains a ratio of 4-caffeoylquinic acid (4-CQA) to total chlorogenic acids (tCGA) (5-CQA/tCGA) of from about 0.1 to about 0.2. More preferably, the green coffee extract comprises from about 6% to about 8% of 4-caffeoylquinic acid and has a total chlorogenic acid concentration that exceeds about 45%. A preferred method of administration consists of administering the green coffee extracts is a dosage of about 200 mg twice a day prior to meals on an empty stomach. | 2015-03-12 |
20150072043 | 9-OXO-HODE AS A BIOMARKER FOR HEALTHY AGING - Using NMR/MS based metabonomics and targeted lipidomics approaches the inventors have explored the metabolic phenotypes of aging and longevity in a cohort compromising centenarians, elderly and young adults. The inventors have identified biomarkers for a reduced risk of developing ageing related chronic inflammatory disorders and propose a method of diagnosing a lifestyle that allows delaying and/or avoiding ageing related chronic inflammatory disorders using 9-oxo-HODE as biomarker. | 2015-03-12 |